HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
— SYVIK ® becomes the first novel Syk inhibitor approved in China —
— SYVIK ® becomes the first novel Syk inhibitor approved in China —